QT
KROS icon

Quantbot Technologies’s Keros Therapeutics KROS Stock Holding History

Quantbot Technologies’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$20 – 1954
2025
Q4 		$20 Sell
1
-385
-100% -$6.75K ﹤0.01% 1653
2025
Q3 		$6.11K Hold
386
– – ﹤0.01% 1643
2025
Q2 		$5.15K Hold
386
– – ﹤0.01% 1562
2025
Q1 		$3.93K Buy
386
+6
+2% +$70 ﹤0.01% 1396
2024
Q4 		$6.01K Buy
+380
New +$19.7K ﹤0.01% 1391
2022
Q3 		– Sell
-6,364
Closed -$175K – 1847
2022
Q2 		$175K Buy
+6,364
New +$279K 0.02% 970
2022
Q1 		– Sell
-200
Closed -$11K – 1859
2021
Q4 		$11K Buy
+200
New +$9.97K ﹤0.01% 1303

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Quantbot Technologies's KROS Position: Q1 2026 in Review

Quantbot Technologies sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 1 share — an estimated $20 sold.

Quantbot Technologies first reported a position in KROS in Q4 2021 and held it in 7 quarters. The position peaked at $175K in Q2 2022. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Quantbot Technologies reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quantbot Technologies sold 1 Keros Therapeutics share in Q1 2026, an estimated $20.
  • Quantbot Technologies first reported a position in Keros Therapeutics in Q4 2021 and held it in 7 quarters.
  • Quantbot Technologies's Keros Therapeutics position peaked at $175K in Q2 2022.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.